Aeterna Zentaris - AEZS Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AEZS shares.
View AEZS analyst ratings or view top-rated stocks.

1 brokers have issued 1-year price objectives for Aeterna Zentaris' shares. Their AEZS share price forecasts range from $37.50 to $37.50. On average, they anticipate the company's share price to reach $37.50 in the next twelve months. This suggests a possible upside of 842.2% from the stock's current price.
View analysts price targets for AEZS or view top-rated stocks among Wall Street analysts.

Aeterna Zentaris' stock was trading at $8.8750 at the beginning of 2022. Since then, AEZS stock has decreased by 55.2% and is now trading at $3.98.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our AEZS earnings forecast.

Aeterna Zentaris Inc. (NASDAQ:AEZS) announced its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.25. The biopharmaceutical company had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.60 million. Aeterna Zentaris had a negative trailing twelve-month return on equity of 20.78% and a negative net margin of 252.34%.

Aeterna Zentaris shares reverse split on the morning of Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Novan (NOVN) and Washington Prime Group (WPG).

Aeterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

Aeterna Zentaris' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AEZS stock can currently be purchased for approximately $3.98.

Aeterna Zentaris (NASDAQ:AEZS) has a market capitalization of $19.34 million and generates $5.26 million in revenue each year. The biopharmaceutical company earns $-8,370,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis.

Aeterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The official website for the company is www.zentaris.com. The biopharmaceutical company can be reached via phone at (843) 900-3223, via email at ir@aezsinc.com, or via fax at 418-948-9191.